Center on Health Equity and Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Partners

Press Releases

Product Approvals and Launches

Media

Clinical Spotlight

Enduring Webinars

Guidelines

Insights

Interviews

Microsites

News Network

OnLocation

Payer Perspectives

Peer Exchange

Podcasts

Post Conference Perspectives

Stakeholder Summit

Week in Review

Conferences

Conference Coverage

Conference Listing

Journals

Submit a Manuscript

All Journals

The American Journal of Managed Care

The American Journal of Accountable Care

Evidence-Based Oncology

Supplements and Featured Publications

Compendia

ALL/AML

Alopecia

Asthma

Atopic Dermatitis

Autoimmune

Biosimilars

Breast Cancer

CLL/SLL

COPD

COVID-19

Cardiovascular

Colorectal Cancer

DLBCL

Dermatology

Diabetes

Duchenne Muscular Dystrophy

Employers

Gastroenterology

Gene Therapy

Graft-vs-Host Disease (GVHD)

Heart Failure

Hemophilia

Idiopathic Pulmonary Fibrosis

Immuno-Oncology

Immunology

Leukemia and Lymphoma

Liver Cancer

Lung Cancer

Medicare

Mental Health

Multiple Myeloma

Multiple Sclerosis

Myasthenia Gravis

Myelodysplastic Syndromes

Myeloproliferative Neoplasms (MPN)

Non–Small Cell Lung Cancer

Obesity

Oncology

Ophthalmology

Ovarian Cancer

Population Health

Psoriasis

Pulmonary Arterial Hypertension

Rare Blood

Reimbursement

Skin Cancer

Sleep

Soft Tissue Sarcoma

Type 1 Diabetes

Events

Upcoming Webinars

CME/CE

Resources

Exclusive Content

Formulary Central

Interactive Tools

Subscribe

Kimberly Rath, PharmD, is a freelance health writer who previously worked as a clinical pharmacist with Elevance Health for a decade. She has also worked for Amerigroup and Sentara Group.

Articles

A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.


Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes

Maggie is an editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.

She has a BA in English from Penn State University. You can connect with Maggie on 

In this retrospective analysis, outcomes data were evaluated on patients receiving care related to extrapleural pneumonectomy for soft tissue sarcoma or bone sarcoma.


Study Sees Limited Success for Extrapleural Pneumonectomy in Sarcoma Cases

In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy. 

Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study

Christina is the associate editorial director of 

 in 2016. She oversees the publication of the print journals, from manuscript submission to publication, and works with the editors in chief and editorial boards to promote the journals.

She has a BS in public health from Rutgers University. You can connect with Christina on 

A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About Us

Contact

Editorial Staff

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Stakeholders

Academia

Health System

Payers

Providers

Topics

Institute for Value-Based Medicine

All Coverage

Event Coverage

About AJMC

AJMC Journals

Anniversary

Author Forms

Authors

Nominate a Rising Leader

1rem

Study Summary: Cardiovascular Safety Profile of Carfilzomib in Multiple Myeloma Clinical Trials

Chari A, Stewart AK, Russell SD, et al. Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. Blood advances. 2018, 2(13):1633-1644. doi: 10.1182/bloodadvances.2017015545.

Articles